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Background. The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors 
is unknown.
Methods. We use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and the 
Centers for Disease Control and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting a 
raltegravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil 
fumarate). We account for confounding and selection bias as well as generalizability by standardization for measured variables, and 
present both observational intent-to-treat and per-protocol estimates.
Results. At treatment initiation, 12% of patients were female, 36% black, 13% Hispanic; median age was 37 years, CD4 count 
321 cells/µL, and viral load 4.5 log10 copies/mL. Two hundred thirty-five patients incurred an AIDS-defining illness or died, and 741 
patients left follow-up. After accounting for measured differences, the 4-year risk was similar among those starting both regimens (ie, 
intent-to treat hazard ratio [HR], 0.96 [95% confidence interval {CI}, .63–1.45]; risk difference, −0.9 [95% CI, −4.5 to 2.7]), as well 
as among those remaining on regimens (ie, per-protocol HR, 0.95 [95% CI, .59–1.54]; risk difference, −0.5 [95% CI, −3.8 to 2.9]).
Conclusions. Raltegravir and efavirenz-based initial antiretroviral therapy have similar 4-year clinical effects. Vigilance regard-
ing longer-term comparative effectiveness of HIV regimens using observational data is needed because large-scale experimental data 
are not forthcoming.
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The comparative effectiveness of human immunodeficiency virus 
(HIV) treatment regimens containing the integrase inhibitor 
raltegravir (RAL) has been demonstrated in randomized experi-
ments [1, 2], at least in terms of 1- to 5-year HIV virologic control. 
Given favorable short-term virologic control, integrase inhibitor–
containing regimens have become the preferred initial treatment 
options in many resource-rich countries, such as the United States 
[3]. However, there has not yet been extensive investigation of 
longer-term comparative effectiveness, especially in terms of clin-
ical endpoints such as HIV disease progression or mortality.
Using data from the National Institutes of Health–funded 
Centers for AIDS Research Network of Integrated Clinical 
Systems (CNICS) cohort, we estimate the 4-year risk of AIDS-
defining illness or mortality for HIV-infected adults initiating 
a regimen of RAL with emtricitabine (FTC) and tenofovir diso-
proxil fumarate (TDF), compared to those initiating a regimen 
of the nonnucleoside reverse transcriptase inhibitor efavirenz 
(EFV) with the same backbone of FTC and TDF. We compare 
risk of incident AIDS or death accounting for measured dif-
ferences in patient characteristics at treatment initiation, as 
well as measured differences between the CNICS cohort and 
the US population of HIV-infected adults, as estimated by the 
Centers for Disease Control and Prevention (CDC) [4]. Based 
on the favorable short-term evidence, we hypothesize that the 
RAL-containing regimen will provide improved 4-year out-
comes compared to the comparator EFV-containing regimen.
METHODS
Study Sample
CNICS is a clinical cohort developed to support population-based 
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HIV-infected adults aged 18 or older who attended a second 
HIV primary care visit at one of 8 Centers for AIDS Research 
sites (Case Western Reserve University; Fenway Community 
Health Center of Harvard University; Johns Hopkins University; 
University of Alabama at Birmingham; University of California, 
San Diego; University of California, San Francisco; University of 
North Carolina; and University of Washington) after 1 January 
1995 (or the site-specific CNICS inception date). Patient demo-
graphics, diagnoses, laboratory measurements, and medications 
are abstracted from point-of-care electronic medical records 
and compiled quarterly. Institutional review boards at each site 
approved study protocols. Patients provided written informed 
consent, or contributed administrative and/or clinical data with 
a waiver of written informed consent where approved by local 
institutional review boards.
Of the >32 000 CNICS patients, 4666 started a first-observed 
antiretroviral therapy regimen consisting of FTC, TDF, and 
either RAL or EFV while under follow-up between 12 October 
2007 (US Food and Drug Administration [FDA] RAL approval 
date) and 1 October 2015, with all drugs started within 7 days 
of each other. History of antiretroviral therapy is collected at 
CNICS entry and patients were classified as antiretroviral 
naive if no evidence of prior treatment was obtained. We also 
excluded the 1335 patients who did not have a detectable (ie, 
>50 copies/mL) HIV-1 RNA viral plasma concentration meas-
ured within 180 days before to 14 days after treatment initia-
tion, because an undetectable viral load may be indicative of
unreported prior treatment. Finally, to allow control for possi-
ble bias, we excluded 270 patients (8%) due to missing data for
race/ethnicity, male sex with men, injection drug use, or base-
line CD4 cell count.
Endpoint Ascertainment
The outcome of interest was a first diagnosis of an AIDS-
defining illness after treatment initiation, or mortality from any 
cause. AIDS-defining illnesses were based on the 1993 CDC 
clinical conditions criteria [6]. Dates of diagnoses of AIDS-
defining illnesses are recorded in the electronic medical record 
at each site and verified before upload to CNICS. Dates of 
deaths are obtained from semiannual site-specific queries to the 
US Social Security Death Index and/or National Death Index.
Target Population
We generalize the estimated comparative effectiveness of RAL- 
vs EFV-containing treatment regimens in CNICS to a target 
population defined by all persons with HIV infection in the 
United States diagnosed in 2008 through 2014. The number of 
HIV-diagnosed persons in categories defined by race/ethnicity, 
sex, age group, and likely mode of transmission (ie, male sex 
with men, injection drug use) was provided by the CDC from 
national HIV surveillance data and accounts for missing infor-
mation [4, 7, 8].
Statistical Methods
We compared the 4-year cumulative risk of incident AIDS 
or death for the RAL- and EFV-containing regimens using a 
treatment-decision design [9], where we restricted analyses to 
new users of treatment [10]. The design mimics a doubly rand-
omized experiment where patients are randomly sampled from 
the target population and randomly allocated to either the RAL-
containing regimen or the active comparator EFV-containing 
regimen [11].
Of course, the CNICS patients were neither randomly sam-
pled from the US HIV-infected population, nor was treatment 
allocated at random. Therefore, we account for nonrandom 
sampling and treatment allocation to the extent possible using 
measured variables. We estimate the observational analogue 
to the intent-to-treat effect of starting regimens regardless of 
subsequent treatment changes [12], as well as the per-protocol 
effect of remaining on initial treatment [13].
Patients were followed from treatment initiation until first 
AIDS-defining illness, death, leaving observation (ie, dropouts), 
or administrative censoring at either 4 years after treatment ini-
tiation or 1 October 2015. To allow for possible 12-month visit 
intervals, patients were considered to have left observation after 
18 months without a documented contact (ie, laboratory meas-
urement or diagnosis). For the observational analogue of the 
per-protocol effect, patients were additionally censored at any 
change in treatment regimen. Two treatment regimen changes 
that were considered exceptions were a change from the RAL 
regimen to another integrase inhibitor–based regimen (includ-
ing fixed-dose combination of elvitegravir, cobicistat, TDF, and 
FTC (FDA approved August 2012) or dolutegravir, TDF, and 
FTC (FDA approved August 2013), as well as a change from 
the EFV regimen to the nonnucleoside reverse transcriptase 
inhibitor regimen of rilpivirine, TDF, and FTC (FDA approved 
August 2011).
Risk of incident AIDS or death for each treatment regimen 
was estimated using the complement of the inverse probability 
(IP)–weighted Kaplan-Meier curve as a function of time since 
treatment initiation [14]. Treatment groups were compared 
using the hazard ratio (HR) and robust 95% confidence intervals 
(CIs) from Cox proportional hazards models [15], IP weighted 
to account for nonrandom sampling, treatment allocation, and 
dropout [16]. Treatment groups were also compared using the 
4-year risk (probability) differences, with 95% CIs estimated
from the standard deviation of 500 nonparametric bootstrap
samples [17]. Time-fixed covariates included in our analysis
were sex, race/ethnicity, age, history of male sex with men, his-
tory of injection drug use, a diagnosis of depression or anxiety,
CD4 cell count, viral load, prevalent AIDS status, and calendar
year, all measured at treatment initiation. Time-varying covar-
iates, used to account for possible bias due to leaving observa-
tion and treatment changes, included annually updated CD4
cell count and viral load. Details of the estimation of IP weights
and the conditions under which these methods provide unbi-
ased (technically, consistent) estimates of risk are provided in 
the Supplementary Appendix. We also provide the bounds [18, 
19] for the treatment effect, which, while wide, apply regardless
of unmeasured bias due to confounding or selection bias.
With 415 and 2646 patients in the RAL and EFV groups, 
respectively, and 196 endpoints in the EFV group, a 4-year risk 
ratio of 0.47 yields 80% statistical power for a 2-sided Wald test 
with type 1 error of 0.05, with expected standard error of 0.27 
and expected 95% CI of .28–.80. SAS software version 9.4 (SAS 
Institute, Cary, North Carolina) was used for analyses.
RESULTS
Compared to the 2646 patients in the EFV group, the 415 
patients in the RAL group were older, with higher CD4 cell 
counts, and were more likely to be female, inject drugs, and have 
a diagnosis of depression/anxiety or AIDS (Table 1). Compared 
to the 296 073 persons with HIV diagnosed between 2008 and 
2014 in the United States, the 3061 patients in the CNICS sam-
ple were older and less likely to be female and black or Hispanic.
During the 4-year follow-up period, 25 of the 415 (6%) 
patients on RAL received a diagnosis of an AIDS-defining 
illness and 14 (3%) died. Of the 2646 patients receiving EFV, 
144 (5%) were diagnosed with an AIDS-defining illness and 
52 (2%) died. Dropout was similar across the treatment groups 
with 23% (94/415) of the RAL group and 24% (647/2646) of the 
EFV group leaving follow-up event-free before 4 years. Details 
of patient follow-up are provided in Supplementary Figure 1.
The crude intent-to-treat 4-year risk of incident AIDS or 
death from any cause, as a function of time from treatment initi-
ation, was 9.9% among those who started the RAL regimen and 
8.1% among those who started the EFV regimen, as shown in 
the upper left panel of Figure 1. The crude intent-to-treat 4-year 
risk difference was 1.8 (95% CI, −1.4 to 5.0), and the hazard 
ratio was 1.32 (95% CI, .94–1.87; Table 2). The bounds for all 
possible values of the 4-year risk difference under no assump-
tions about confounding or selection bias were –35% under the 
best-case scenario for RAL, and 65% under the worst-case sce-
nario for RAL (Supplementary Figure 2).
After accounting for nonrandom sampling, treatment alloca-
tion, and dropout, the IP-weighted intent-to-treat 4-year risk of 
incident AIDS or death from any cause was 8.4% among those 
who started the RAL regimen and 9.3% for those who started 
the EFV regimen, as shown in the upper right panel of Figure 1. 
The IP-weighted intent-to-treat 4-year risk difference was −0.9 
(95% CI, −4.5 to 2.7), and the hazard ratio was 0.96 (95% CI, 
.63–1.45; Table 2). Changes in the intent-to-treat hazard ratio 
due to each of nonrandom sampling, treatment allocation, and 
dropout are detailed in Supplementary Table 1.
Eighteen percent (76/413) of the RAL group, and 8% 
(201/2646) of the EFV group, had a protocol-allowed treat-
ment change before incurring an outcome or completing the 
study. Twenty percent (84/415) of the RAL group, and 28% 
(733/2646) of the EFV group, had a protocol-ending treat-
ment change before incurring an outcome or completing the 
study. In the observed data, the crude per-protocol 4-year 
Table 1. Characteristics at Treatment Initiation Among 3061 Human Immunodeficiency Virus (HIV)–Infected Adults in Care Between 12 October 2007 and 








US Target Population 
(n = 296 073)
Female sex 19 (78) 11 (302) 12 (380) 21 (63 140)
Black race 33 (135) 36 (958) 36 (1093) 45 (134 646)
Hispanic ethnicity 9 (39) 13 (344) 13 (383) 22 (63 830)
Age, y, median (IQR) 40 (32–48) 37 (29–46) 37 (29–46) NA
Age, y … … … …
 18–24 6 (25) 11 (296) 10 (321) 20 (59 274)
 25–34 27 (114) 31 (833) 31 (947) 29 (84 781)
 35–44 30 (124) 29 (776) 29 (900) 23 (68 708)
 45–54 26 (107) 22 (582) 23 (689) 19 (55 800)
 ≥55 11 (45) 6 (159) 7 (204) 9 (27 510)
Male sex with men 64 (267) 72 (1907) 71 (2174) 65 (192 742)
Injection drug use 16 (67) 11 (300) 12 (367) 8 (23 134)
AIDS diagnosisb 15 (61) 12 (310) 12 (371) NA
Depression or anxiety 25 (105) 21 (553) 22 (658) NA
CD4 count, cells/µL, median (IQR) 347 (181–509) 319 (179–459) 321 (180–466) NA
Viral load, copies/mL, median (IQR) 4.4 (3.5–5.0) 4.5 (3.8–5.1) 4.5 (3.7–5.1) NA
Calendar year, median (IQR) 2011 (2010–2013) 2010 (2009–2012) 2010 (2009–2012) 2011 (2009–2013)
Data are presented as percentage (No.) unless otherwise indicated.
Abbreviations: IQR, interquartile range; NA, not available; US, United States.
aBoth regimens included the same backbone of emtricitabine and tenofovir disoproxil fumarate.
bPrevalent AIDS diagnosis at treatment initiation.
risk of incident AIDS or death from any cause, as a function 
of time from treatment initiation, was 8.6% among those 
in the RAL group and 6.5% for those in the EFV group, as 
shown in the lower left panel of Figure  1. The crude per- 
protocol 4-year risk difference was 2.1 (95% CI, −1.0 to 
5.1), and the HR was 1.41 (95% CI, .96–2.07; Table 2). After 
accounting for nonrandom sampling, treatment alloca-
tion, dropout, and treatment changes, the IP-weighted per-  
protocol 4-year risk of incident AIDS or death from any cause 
was 7.2% among those who started the RAL regimen and 
7.7% for those who started the EFV regimen, as shown in the 
lower right panel of Figure 1. The IP-weighted per-protocol  
4-year risk difference was −0.5 (95% CI, −3.8 to 2.9), and 
the HR was 0.95 (95% CI, .59–1.54; Table 2). Changes in the 
per-protocol HR due to each of nonrandom sampling, treat-
ment allocation, dropout, and treatment changes are detailed 
in Supplementary Table 1.
DISCUSSION
In a large multisite clinical cohort, we first observed apparently 
higher risk of 4-year HIV disease progression among patients 
starting and remaining on an antiretroviral therapy combina-
tion including RAL, compared to those starting and remaining 
on a combination including EFV with the same backbone using 
a per-protocol analysis. However, the apparent difference in 
incident AIDS or all-cause death was largely eliminated upon 
jointly accounting for nonrandom sampling, treatment allo-
cation, and dropout. Crude and adjusted results were similar 
when we ignored treatment changes using an observational 
equivalent of intent-to-treat analysis. Findings indicate a sim-
ilar 4-year clinical effect of RAL or EFV initial antiretroviral 
therapy, with the same backbone of FTC and TDF.
Existing randomized evidence has concentrated on relatively 
short-term virologic endpoints and lack the statistical power to 
evaluate clinical endpoints, including mortality. Efavirenz and RAL 
Figure 1. Risk of incident AIDS or death from any cause over 4 years from treatment initiation among 3061 human immunodeficiency virus–infected adults in care between 
12 October 2007 and 1 October 2015. Solid line represents the efavirenz regimen, and dashed line represents the raltegravir regimen. Upper panels represent intent-to-treat 
analyses with the left panel depicting the crude results, and right panel the inverse probability (IP)–weighted results (accounting for nonrandom sampling, treatment alloca-
tion, and dropout). Lower panels represent per-protocol analyses with the left panel again representing crude results, and the right panel the IP-weighted results (accounting 
for nonrandom sampling, treatment allocation, dropout, and treatment changes).
have only been compared once in a large randomized clinical trial 
of treatment-naive patients [1, 20]. In that trial, RAL or EFV was 
paired with FTC and tenofovir: virologic suppression rates were 
similar at 48 and 96 weeks. After 5 years of follow-up, virologic 
suppression was greater in the RAL arm, driven predominantly 
by discontinuation in the EFV arm [21]. Serious clinical events 
and deaths were uncommon and similar between arms. Other 
integrase inhibitors have been compared to EFV in randomized 
trials in treatment-naive patients and results were similar to those 
seen with RAL. One trial demonstrated superiority of the integrase 
inhibitor in maintaining virologic suppression over 96 weeks, again 
driven by discontinuations in an EFV arm [22, 23], and another 
trial demonstrated similar viral suppression outcomes between the 
integrase inhibitor arm and an EFV arm [24–26].
Our results are subject to limitations. Foremost, patient sam-
pling, treatment allocation, dropout, and treatment changes 
were not randomized. It does not appear that sicker individ-
uals (defined by lower CD4 cell count, higher viral load, and 
prevalent AIDS diagnosis) were more likely to receive the RAL 
regimen. However, physicians may be channeling patients to 
RAL for reasons not captured in the set of adjustment variables. 
For example, RAL may be prescribed preferentially for those 
with cardiovascular or liver disease [27]. Moreover, patients 
expected to be less compliant may be prescribed RAL prefer-
entially, thereby causing a weakened protective effect of RAL vs 
EFV. Dropout and treatment changes were relatively balanced 
across treatment groups. While we accounted for differences 
due to measured variables, there might have been unmeasured 
causes in common with AIDS or death, which could bias our 
results. Second, our results are relatively imprecise due to the 
small number of outcomes in the RAL group, which is a result 
of a combination of recent uptake and treatment effectiveness. 
Indeed, we allow patients to enter follow-up beginning 12 
October 2007 when RAL was FDA approved, but few patients 
started first-line RAL before 2009 when it was recommended 
in the US Department of Health and Human Services guide-
lines. In particular, the small size of the RAL group precludes 
our ability to explore how risk differs for subgroups (eg, age). 
Moreover, the improved effectiveness of antiretroviral ther-
apies and the small number of treatment-naive patients with 
long-term integrase inhibitor experience make differences in 
risk especially difficult to detect in randomized or nonrand-
omized studies. Third, our results might be biased due to meas-
urement errors. However, data from both the CNICS and the 
CDC are produced under strict quality guidelines. Moreover, 
key variables used here (including demographic characteristics, 
treatment regimen, AIDS diagnoses, and deaths) are carefully 
collected and reviewed or adjudicated and likely measured with 
only negligible error. We did not provide details regarding cause 
of death; quantifying cause of death is difficult generally, and 
particularly so in the modern era of HIV as relatively sharply 
defined AIDS-related deaths recede and a large set of heteroge-
neous causes emerges. Fourth, we assume correct specification 
of the models used to estimate the inverse probability weights.
The data employed here are among the highest quality and 
quantity available in the United States from HIV observa-
tional cohorts, and experimental evidence is not forthcoming. 
Observational cohort studies collecting comprehensive longi-
tudinal data provide a valuable source of information supple-
menting estimates from randomized trials. In the absence of 
data from randomized trials, rich prospective observational 
data coupled with logically principled quantitative methods 
Table 2. Risk of Incident AIDS or Death From Any Cause Over 4 Years From Treatment Initiation Among 3061 Human Immunodeficiency Virus–Infected 
Adults in Care Between 12 October 2007 and 1 October 2015
Analysis Patients, No. Person-years, No. Outcomes, No. 4-Year Risk 4-Year Risk Difference (95% CI) Hazard Ratio (95% CI)
Intent-to-treat analyses
 Crude
  Efavirenza 2646 8604.9 196 8.1 0 1
  Raltegravira 415 1232.6 39 9.9 1.8 (−1.4 to 5.0) 1.32 (.94–1.87)
 IP-weightedb
  Efavirenza … … … 9.3 0 1
  Raltegravira … … … 8.4 −0.9 (−4.5 to 2.7) 0.96 (.63–1.45)
Per-protocol analyses
 Crude
  Efavirenza 2646 6858.8 143 6.5 0 1
  Raltegravira 415 1072.9 32 8.6 2.1 (−1.0 to 5.1) 1.41 (.96–2.07)
 IP-weightedb
  Efavirenza … … … 7.7 0 1
  Raltegravira … … … 7.2 −0.5 (−3.8 to 2.9) 0.95 (.59–1.54)
Abbreviations: CI, confidence interval; IP, inverse probability.
aBoth regimens included the same backbone of emtricitabine and tenofovir disoproxil fumarate.
bResults from IP-weighted Kaplan-Meier and Cox regression estimates with IP weights for sampling, treatment regimen, and dropout (and regimen change for per-protocol analyses).
provide the best available evidence for assessment of compara-
tive effectiveness. In our study, reweighting of the observed data 
[28, 29] accounted for measured imbalances in treatment allo-
cation and dropout (and treatment stops) and so removed con-
founding and selection bias associated with observed variables. 
This reweighting provides an internally valid estimate of the 
treatment effect, assuming we measured (and correctly mod-
eled) a correct set of variables. The data were further reweighted 
to account for measured imbalances between the CNICS sample 
and the CDC population, and therefore removed sampling bias 
associated with observed variables. This accounting provides 
an externally valid estimate of the treatment effect, assuming 
we measured (and correctly modeled) a correct set of variables. 
Although there is some experimental evidence for a short and 
moderate-term advantage of integrase inhibitor regimens on 
viremia, our analysis indicates a similar clinical effect to 4 years. 
Continuing assessment of the longer-term comparative effec-
tiveness of these regimens using observational data is needed.
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